The slow-growing primary brain tumors (1, 2), WHO grade II and III gliomas (hereon, referred to as, lower-grade gliomas) are diagnosed based on molecular features (presence or absence of IDH1/2 mutations and 1p/19q co-deletion) (1, 2). Here, IDH1 is linked to central nervous system cancer.